Expertise in
6
conditions

Ahmet H. Elmaagacli

Hamburg, HH, DE 
Expertise in
6
conditions
Hamburg, HH, DE 

Overview

Ahmet Elmaagacli practices practicing medicine in Hamburg, Germany.

Mr. Elmaagacli is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Leukemia, Cytomegalovirus Infection, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Hamburg, HH, Germany
Other Locations
AK St. Georg
St. Georg, HH, Germany
HELIOS Schwerin
Schwerin, MV, Germany
Essen, NW, Germany
Altona, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
View 1 Less Clinical Trial

42 Total Publications

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.
Journal: Journal of hematology & oncology
Published: April 06, 2026

Frequently Asked Questions about Ahmet H. Elmaagacli

Is Ahmet H. Elmaagacli a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Ahmet H. Elmaagacli is classified as an Distinguished expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ahmet H. Elmaagacli participate in research or clinical trials?

Yes. Ahmet H. Elmaagacli has published 42 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Ahmet H. Elmaagacli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Elmaagacli's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile